Antibody polypeptides that antagonize CD40L

US11180567B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Domantis Limited · GB

Inventors

• Steven G. Nadler · Princeton, US
• James K. Tamura · Yardley, US
• Laura Price · Langhorne, US
• Robert P. Rehfuss · North Wales, US
• Suzanne J. Suchard · Wilmington, US
• Anish Suri · Beerse, BE
• James W. Bryson · Langhorne, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Steven Grant · Cambridge, GB
• Olga Ignatovich · Cambridge, GB
• Philip Drew · Histon, GB

Key dates

• Filing date: Dec 12, 2018
• Grant date: Nov 23, 2021
• Expiry date: Dec 12, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.